Source: FirstWord Pharma

Catamaran Bio: Catamaran Bio Expands Collaboration for CARNK Cell Engineering with the University of Minnesota and Secures an Exclusive Patent License to Next Generation Manufacturing Technologies

-- Next phase of collaboration to primarily focus on continued advancement of transposon engineering for allogeneic CAR-NK cell therapies and optimization of CAR-NK cell manufacturability -- -- ...

Read full article »
Est. Annual Revenue
$5.0-25M
Est. Employees
100-250
Alvin Shih's photo - President & CEO of Catamaran Bio

President & CEO

Alvin Shih

CEO Approval Rating

90/100

Read more